Aiosyn, a company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council). This additional funding allows Aiosyn to accelerate its mission: increasing the adoption of artificial intelligence in pathology diagnostics and improving the chances of cancer patients worldwide.
Related news items
Aiosyn raises EUR 2 million to develop AI-powered algorithms to support pathologists with clinical diagnostics21 December 2022
Nijmegen, the Netherlands – Aiosyn is developing a diagnostics platform that uses artificial intelligence to support pathologists with more accurate and efficient clinical diagnostics.read more
Aiosyn selected as finalist for OostNL's Startversneller vote now!18 October 2022
The 6 finalists of the election “Starter with impact Eastern Netherlands 2022” have been announced and Radboudumc’s Aiosyn is one of them.read more